In addition, the activation of cyclin D-CDK4/6-Rb, activation of other proliferation pathways, changes in the tumor microenvironment, and regulation of tumor metabolism may also lead to the emergence of acquired drug resistance [132]. Here, RB1 is linked to neoplasm.